Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani

Clinical and Experimental Immunology

Volumn 140, Issue 1, 2005, Pages 149-156

  Garg, R ^a   Gupta, S K ^a   Tripathi, P ^b   Naik, S ^b   Sundar, S ^c   Dube, Anuradha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^c BANARAS HINDU UNIVERSITY   (India)

Author keywords

Cellular immune response; Cured hamsters; Cured patients; IFN NO production; LTT; Lymphocytes; Macrophages

Indexed keywords

GAMMA INTERFERON; INTEGRAL MEMBRANE PROTEIN; MEMBRANE PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDEMIC DISEASE; HAMSTER; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LEISHMANIA DONOVANI; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN PURIFICATION; RELAPSE; TH1 CELL; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; ANIMALS; ANTIGENS, PROTOZOAN; CELL LINE; CHILD; CHILD, PRESCHOOL; CRICETINAE; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MACROPHAGES; MALE; MEMBRANE PROTEINS; MESOCRICETUS; MITOGENS; NITRIC OXIDE; PROTOZOAN PROTEINS; SOLUBILITY;

EID: 16244405883     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02745.x     Document Type: Article

References (46)

1. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6:849-54.
2. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95:239-43.
3. Burns JM Jr, Scott JM, Carvalho EM, Russo DM, March CJ, Van Ness KP, Reed SG. Characterization of a membrane antigen of Leishmania amazonensis that stimulates human immune responses. J Immunol 1991; 146:742-8.
4. Skeiky YA, Kennedy M, Kaufman D et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol 1998; 161:6171-9.
5. Russo DM, Burns JM Jr, Carvalho EM, Armitage RJ, Grabstein KH, Button LL, McMaster WR, Reed SG. Human T cell responses to gp63, a surface antigen of Leishmania. J Immunol 1991; 147:3575-80.
6. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988; 168:1675-84.
7. Murray HW, Rubin BY, Rothermel CD. Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. J Clin Invest 1983; 72:1506-10.
8. Carvalho EM, Johnson WD, Barreto E, Marsden PD, Costa JL, Reed S, Rocha H. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 1985; 135:4144-8.
9. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M. Conceicao-Silva F, Modlin RL. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 1993; 91:1390-5.
10. Murray PJ, Spithill TW, Handman E. Characterisation of integral membrane proteins of Leishmania major by Triton X-114. Production and analysis of vaccination effect in mice. Infect Immun 1989; 57:2203-9.
11. McConville MJ, Bacic A, Mitchell GF, Handman E. Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor. Proc Natl Acad Sci USA 1987; 84:8941-5.
12. Etges RJ, Bouvier J, Hoffman R, Bordier C. Evidence that the major surface proteins of three Leishmania species are structurally related. Mol Biochem Parasitol 1985; 14:141-9.
13. Heath S, Chance ML, Hommel M, Crompton JM. Cloning of a gene encoding the immunodominant surface antigen of Leishmania donovani promastigotes. Mol Biochem Parasitol 1987; 23:211-22.
14. Garg R, Srivastava JK, Pal A, Naik S, Dube A. Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis. Vaccine 2005; 23:1189-96.
15. Scott P, Pearce E, Notovitz P, Sher A. Vaccination against cutaneous leishmaniasis in murine model II. Immunologic properties of protective and nonprotective sub fractions of a soluble promastigote extract J Immunol 1987; 139:3118-25.
16. Scott P, Pearce E, Natovitz P, Sher A. Vaccination against cutaneous leishmaniasis in a murine model I. Introduction of protective immunity with a soluble extract of promastigotes. J Immunol 1987; 139:221-7.
17. Choudhury A, Guru PY, Saxena RP, Tandon A, Saxena KC. Enzyme linked immunosorbant assay in diagnosis of kala-azar in Bhadohi (Varanasi) India. Trans R Soc Trop Med Hyg 1990; 84:363-7.
18. Modabber F. Development of vaccines against leishmaniasis. Scand J Infect Dis Supplement 1990; 76:72-8.
19. Jaffe CL, McMahon-Pratt D. Serodiagnostic assay for visceral leishmaniasis employing monoclonal antibodies. Trans Roy Soc Trop Med Hyg 1987; 81:587-94.
20. Reed SG, Badaro R, Lloyd RMC. Identification of specific and cross-reactive antigens of L. donovani chagasi by human infection sera. J Immunol 1987; 138:1596-601.
21. Jardim A, Tolson DL, Turco SJ, Pearson TW, Olafson RW. The Leishmania donovani lipophosphoglycan T lymphocyte reactive component is a tightly associated protein complex. J Immunol 1991; 147:3538-44.
22. Jensen AT, Gasim S, Ismail A, Gaafar A, Kuertzhals JA, Kemp M, El-hassan AM. Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11. Scand J Immunol 1998; 48:103-9.
23. Russo DM, Jardim EM, Carvelho EM, Sieath PR, Armitage RJ, Olafson RW, Reed SG. Mapping human T cell epitopes in Leishmania gp63 identification of cross reactive and species specific epitopes. J Immunol 1993; 150:932-9.
24. Chulay JD, Bryceson AD. Cultivation of amastigotes of Leishmania donovani in smear of splenic aspirates from patients with visceral leishmaniasis. M Am J Trop Med Hyg 1983; 32:475-9.
25. Dube A, Sharma P, Srivastava JK, Misra A, Naik S, Katiyar JC. Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology 1998; 116:219-21.
26. Bordier C. Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem 1981; 256:1604-7.
27. Smyth JA, Coppel RL, Brown GV, Ramasamy R, Kemp DJ, Anders RF. Identification of two integral membrane proteins of Plasmodium falciparum. Proc Natl Acad Sci USA 1988; 85:5195-9.
28. Lowry OH, Rosebrough NJ, Farr AL, Randal RJ. Protein measurement with folin-phenol reagent. J Biol Chem 1951; 193:265-75.
29. Ding AH, Nathan CF, Stuetr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophage. J Immunol 1988; 141:2407-12.
30. Singh N, Dube A. Fluorescent Leishmania: Applications to antileishmanial drug testing. Am J Trop Med Hyg 2004; 71:400-2.
31. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2:845-58.
32. Dwyer DM. Isolation & partial characterisation of surface membranes from Leishmania donovani promastigotes. J Protozool 1980; 27:176-82.
33. Khalil EAG, El Hassan AM, Zijlstra EE et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomized, double blind, BCG-controlled trial in Sudan. Lancet 2000; 356:1565-9.
34. Kahl LP, Scott CA, Lelchguk R, Gregoriadis G, Liew RY. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen liposomes. Optimization and assessment of the requirement for intravenous immunizaiton. J Immunol 1989; 142:4441-9.
35. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect interleukin-12 in a vaccine against Leishmania major. Science 1994; 263:235-7.
36. Champsi J, McMohan-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun 1988; 56:3272-9.
37. Jaffe CL, Rachamin N, Sarfestein R. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis. J Immunol 1990; 144:699-706.
38. White AC Jr, McMahon-Pratt D. Prophylactic immunization against experimental Leishmania donovani infection by use of a purified protein vaccine. J Infect Dis 1990; 161:1313-4.
39. McConville MJ, Bacic A, Mitchell GF, Handman E. Lipophosphoglycon of Leishmania major that vaccinate against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor. Proc Natl Acad Sci USA 1987; 84:8941-5.
40. Rogers MV, Davern KM, Smythe J, Mitchell GF. Immunoblotting analysis of the major integral membrane protein antigens of Schistosoma japonicum. Mol Biochem Parasitol 1988; 29:77-87.
41. Balber AE, Ho LM. Trypanosoma brucei gambiense: pantidioning of glyco peptides of blood stream and procyclic forms in Triton X-114. Exp Parasitol 1988; 65:290-3.
42. Melby PC, Tryon VV, Chandrasekar B, Freeman GL. Cloning of syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect Immun 1998; 66:2135-42.
43. Hibbs JB, Taintor RR, Vavrin Z. Macrophage cytotoxicity: role for 1-arginine deiminase and imino nitrogen oxidation to nitrite. Science 1987; 235:473-6.
44. Liew FY, Li Y, Moss D, Parkinson C, Rogers MV, Moncada S. Resistance to Leishmania major infection correlates with the induction of nitric oxide synthase in murine macrophages. Eur J Immunol 1991; 21:3009-14.
45. Taylor-Robinson AW, Phillips RS, Severn A, Moncada S, Liew FY. The role of TH1 and TH2 cells in a rodent malaria infection. Science 1993; 260:1931-4.
46. Assreuy J, Cunha FQ, Epperlein M, Noronha AN, Dutra A, O'Donnel CA, Liew FY, Moncada S. Production of nitric oxide and super oxide by activated macrophages and killing of Leishmania major. Eur J Immunol 1994; 24:672-6.